These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 23983134)

  • 1. Low- versus high-dose rituximab for rheumatoid arthritis: a systematic review and meta-analysis.
    Bredemeier M; de Oliveira FK; Rocha CM
    Arthritis Care Res (Hoboken); 2014 Feb; 66(2):228-35. PubMed ID: 23983134
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Updated systematic review and meta-analysis of randomized controlled trials comparing low- versus high-dose rituximab for rheumatoid arthritis.
    Bredemeier M; Campos GG; de Oliveira FK
    Clin Rheumatol; 2015 Oct; 34(10):1801-5. PubMed ID: 26070536
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-Term Efficacy and Safety of Biosimilar CT-P10 Versus Innovator Rituximab in Rheumatoid Arthritis: 48-Week Results from a Randomized Phase III Trial.
    Suh CH; Yoo DH; Berrocal Kasay A; Chalouhi El-Khouri E; Cons Molina FF; Shesternya P; Miranda P; Medina-Rodriguez FG; Wiland P; Jeka S; Chavez-Corrales J; Linde T; Hrycaj P; Abello-Banfi M; Hospodarskyy I; Jaworski J; Piotrowski M; Brzosko M; Krogulec M; Shevchuk S; Calvo A; Andersone D; Park W; Shim SC; Lee SJ; Lee SY
    BioDrugs; 2019 Feb; 33(1):79-91. PubMed ID: 30719632
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation.
    Malottki K; Barton P; Tsourapas A; Uthman AO; Liu Z; Routh K; Connock M; Jobanputra P; Moore D; Fry-Smith A; Chen YF
    Health Technol Assess; 2011 Mar; 15(14):1-278. PubMed ID: 21439251
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ultra-low dose of rituximab in rheumatoid arthritis: study protocol for a randomised controlled trial.
    den Broeder AA; Verhoef LM; Fransen J; Thurlings R; van den Bemt BJF; Teerenstra S; Boers N; den Broeder N; van den Hoogen FHJ
    Trials; 2017 Aug; 18(1):403. PubMed ID: 28854956
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Infliximab and methotrexate in the treatment of rheumatoid arthritis: a systematic review and meta-analysis of dosage regimens.
    Zintzaras E; Dahabreh IJ; Giannouli S; Voulgarelis M; Moutsopoulos HM
    Clin Ther; 2008 Nov; 30(11):1939-55. PubMed ID: 19108784
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of various repeat treatment dosing regimens of rituximab in patients with active rheumatoid arthritis: results of a Phase III randomized study (MIRROR).
    Rubbert-Roth A; Tak PP; Zerbini C; Tremblay JL; Carreño L; Armstrong G; Collinson N; Shaw TM;
    Rheumatology (Oxford); 2010 Sep; 49(9):1683-93. PubMed ID: 20463186
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis.
    Keystone E; Fleischmann R; Emery P; Furst DE; van Vollenhoven R; Bathon J; Dougados M; Baldassare A; Ferraccioli G; Chubick A; Udell J; Cravets MW; Agarwal S; Cooper S; Magrini F
    Arthritis Rheum; 2007 Dec; 56(12):3896-908. PubMed ID: 18050221
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multiple courses of rituximab produce sustained clinical and radiographic efficacy and safety in patients with rheumatoid arthritis and an inadequate response to 1 or more tumor necrosis factor inhibitors: 5-year data from the REFLEX study.
    Keystone EC; Cohen SB; Emery P; Kremer JM; Dougados M; Loveless JE; Chung C; Wong P; Lehane PB; Tyrrell H
    J Rheumatol; 2012 Dec; 39(12):2238-46. PubMed ID: 23027887
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the safety of rituximab in combination with a tumor necrosis factor inhibitor and methotrexate in patients with active rheumatoid arthritis: results from a randomized controlled trial.
    Greenwald MW; Shergy WJ; Kaine JL; Sweetser MT; Gilder K; Linnik MD
    Arthritis Rheum; 2011 Mar; 63(3):622-32. PubMed ID: 21360491
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of rituximab on physical function and quality of life in patients with rheumatoid arthritis previously untreated with methotrexate.
    Rigby W; Ferraccioli G; Greenwald M; Zazueta-Montiel B; Fleischmann R; Wassenberg S; Ogale S; Armstrong G; Jahreis A; Burke L; Mela C; Chen A
    Arthritis Care Res (Hoboken); 2011 May; 63(5):711-20. PubMed ID: 21557525
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biologics or tofacitinib for people with rheumatoid arthritis unsuccessfully treated with biologics: a systematic review and network meta-analysis.
    Singh JA; Hossain A; Tanjong Ghogomu E; Mudano AS; Maxwell LJ; Buchbinder R; Lopez-Olivo MA; Suarez-Almazor ME; Tugwell P; Wells GA
    Cochrane Database Syst Rev; 2017 Mar; 3(3):CD012591. PubMed ID: 28282491
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Infection risks of rituximab versus non-rituximab treatment for rheumatoid arthritis: A systematic review and meta-analysis.
    Shi Y; Wu Y; Ren Y; Jiang Y; Chen Y
    Int J Rheum Dis; 2019 Aug; 22(8):1361-1370. PubMed ID: 31099191
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks.
    Cohen SB; Emery P; Greenwald MW; Dougados M; Furie RA; Genovese MC; Keystone EC; Loveless JE; Burmester GR; Cravets MW; Hessey EW; Shaw T; Totoritis MC;
    Arthritis Rheum; 2006 Sep; 54(9):2793-806. PubMed ID: 16947627
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sarilumab for Previously-Treated Moderate or Severe Rheumatoid Arthritis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Bermejo I; Ren S; Simpson E; Clowes M; Scott DL; Young A; Stevenson M
    Pharmacoeconomics; 2018 Dec; 36(12):1427-1437. PubMed ID: 29882210
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Down-titration and discontinuation strategies of tumor necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity.
    van Herwaarden N; den Broeder AA; Jacobs W; van der Maas A; Bijlsma JW; van Vollenhoven RF; van den Bemt BJ
    Cochrane Database Syst Rev; 2014 Sep; (9):CD010455. PubMed ID: 25264908
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Rituximab in rheumatoid arthritis: a systematic review of efficacy and safety].
    Hernández-Cruz B; García-Arias M; Ariza Ariza R; Martín Mola E
    Reumatol Clin; 2011; 7(5):314-22. PubMed ID: 21925447
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A systematic review and meta-analysis of rituximab combined with methotrexate versus methotrexate alone in the treatment of rheumatoid arthritis.
    Wang Z; Bao HW; Ji Y
    Medicine (Baltimore); 2020 Feb; 99(8):e19193. PubMed ID: 32080104
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The efficacy and safety of rituximab for the treatment of active rheumatoid arthritis: a systematic review and meta-analysis of randomized controlled trials.
    Lee YH; Bae SC; Song GG
    Rheumatol Int; 2011 Nov; 31(11):1493-9. PubMed ID: 20473756
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy, Safety and Pharmacokinetics of Up to Two Courses of the Rituximab Biosimilar CT-P10 Versus Innovator Rituximab in Patients with Rheumatoid Arthritis: Results up to Week 72 of a Phase I Randomized Controlled Trial.
    Yoo DH; Suh CH; Shim SC; Jeka S; Molina FFC; Hrycaj P; Wiland P; Lee EY; Medina-Rodriguez FG; Shesternya P; Radominski S; Stanislav M; Kovalenko V; Sheen DH; Myasoutova L; Lim MJ; Choe JY; Lee SJ; Lee SY; Kim SH; Park W
    BioDrugs; 2017 Aug; 31(4):357-367. PubMed ID: 28612179
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.